AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.
At 17, I began to flirt with madness. My bipolar disorder started to take over my mind; and my thoughts suddenly became out of line, and quicker, too. Suddenly, almost overnight, I was thinking fast, ...